Pluri Inc. (PLUR)
PLUR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/0001213900-26-098862-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | PLUR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001158780 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | NV |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $1.0M |
| Net income | -$23.8M |
| Operating income | -$24.9M |
| Net margin | -2344.6% |
| Operating margin | -2454.5% |
| Revenue growth | -24.0% |
| Cash | $3.5M |
| Total assets | $24.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 14.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $3.5M cash; operating cash flow -$4.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 14,375,922 (2026-11-11); 9,253,897 a year earlier; 41,480,172 three years earlier. 3y figure adjusted for splits (1-for-8 overall). | Cover page 2026-11-11 |
| Reverse splits, 3 years | 1; latest 1-for-8 on 2024-04-01 | Source 2024-04-01 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-08-28 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-07-13 |
| Auditor | Kesselman & Kesselman C.P.A.s, Haifa, Israel | PCAOB Form AP 2026-09-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | $759K | -$10.4M | -$4.5M | $3.5M | No debt tags | $1.5M | 10-Q 2026-11-12 |
| Q4 2026 2026-06-30 | $335K | -$5.9M | -$4.4M | $3.5M | No debt tags | $1.0M | 10-K 2026-09-10 |
| Q3 2026 2026-03-31 | $167K | -$5.5M | -$4.5M | $3.4M | No debt tags | $1.1M | 10-Q 2026-05-14 |
| Q2 2026 2025-12-31 | $198K | -$6.5M | -$5.2M | $4.7M | No debt tags | $1.3M | 10-Q 2026-02-12 |
| Q1 2026 2025-09-30 | $316K | -$5.8M | -$5.4M | $4.3M | No debt tags | $1.3M | 10-Q 2026-11-12 |
| Q4 2025 2025-06-30 | $398K | -$7.6M | -$5.2M | $5.9M | No debt tags | $1.3M | 10-K 2026-09-10 |
| Q3 2025 2025-03-31 | $427K | -$6.1M | -$4.3M | $8.5M | $24.9M | $1.0M | 10-Q 2026-05-14 |
| Q2 2025 2024-12-31 | $185K | -$3.0M | -$4.6M | $7.2M | $23.8M | $678K | 10-Q 2026-02-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-1 | 2026-10-06 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-09-10 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-30 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 956 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.3% |
| 1 month | +11.7% |
| 3 months | -36.7% |
| Year to date | -64.9% |
| 1 year | -74.9% |
| From 52-week high | -73.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ABOS | Acumen Pharmaceuticals Inc. | $0.2160 | +0.93% | $15.6M |
| ESLA | Estrella Immunopharma Inc. | $0.3800 | -26.07% | $16.5M |
| ATYR | aTyr Pharma Inc. | $5.24 | -14.17% | $13.4M |
| PASG | Passage Bio Inc. | $4.13 | -2.82% | $13.3M |
| JSPR | Jasper Therapeutics Inc. | $11.77 | -13.96% | $13.1M |
| DYAI | Dyadic International Inc. | $0.3200 | -2.14% | $12.8M |
| BSEM | BioStem Technologies Inc. | $0.9601 | -8.56% | $18.4M |
| BCDA | BioCardia Inc. | $0.7901 | -4.92% | $12.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier